In infections with Shiga toxin–producing Escherichia coli, which intervention is contraindicated?

In infections with Shiga toxin–producing Escherichia coli, which intervention is contraindicated?

• A. Rehydration
• B. Metoclopramide
• C. Antibiotics
• D. Ondansetron

Answer: (C)

Shiga toxin–producing E. coli infections are driven by the toxin itself, which can damage small blood vessels and kidneys, putting patients at risk for hemolytic uremic syndrome, especially in children. Antibiotics can cause the bacteria to lyse and release more Shiga toxin into the gut, potentially increasing toxin exposure and the risk of HUS. For this reason, antibiotic therapy is avoided in suspected STEC infections. The mainstay of management is supportive care with adequate fluids and electrolyte repletion to prevent dehydration and maintain kidney perfusion. Anti-emetics like metoclopramide or ondansetron can help control nausea and vomiting to improve hydration, though they carry their own side-effect considerations. In short, the intervention to avoid is antibiotic treatment because it can worsen toxin-mediated injury and the risk of HUS.

Shiga toxin–producing E. coli infections are driven by the toxin itself, which can damage small blood vessels and kidneys, putting patients at risk for hemolytic uremic syndrome, especially in children. Antibiotics can cause the bacteria to lyse and release more Shiga toxin into the gut, potentially increasing toxin exposure and the risk of HUS. For this reason, antibiotic therapy is avoided in suspected STEC infections. The mainstay of management is supportive care with adequate fluids and electrolyte repletion to prevent dehydration and maintain kidney perfusion. Anti-emetics like metoclopramide or ondansetron can help control nausea and vomiting to improve hydration, though they carry their own side-effect considerations. In short, the intervention to avoid is antibiotic treatment because it can worsen toxin-mediated injury and the risk of HUS.